RHACE2
APN01 – Our work on a potential drug candidate for COVID-19 treatment
We are developing a potential drug candidate APN01* (alunacedase alfa), based on our proprietary ACE2 platform to address the growing global health threat of COVID-19. APN01 is ideally suited to prevent the infection with SARS-CoV-2, reduce injury to multiple organs and mitigate the deleterious consequences of established viral infection. ACE2, and its role in respiratory...
April 2, 2020
1 Comment
APEIRON’s respiratory drug product to start pilot clinical trial to treat coronavirus disease COVID-19 in China.
Investigator Initiated Trial (IIT) to start in China, with an international team of experts from China, Austria, and Canada. 24 patients with severe COVID-19 to be treated in a randomized, dual-arm trial with Apeiron’s ACE2 drug product APN01 APN01 was previously proven to be safe and well tolerated in Phase I and Phase II clinical...
February 26, 2020
No Comments
